Compound ID	CDAMM00795
Common name	Reserpine
IUPAC name	methyl 6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate
Molecular formula	C₃₃H₄₀N₂O₉

Experimental data

Retention time	12.28
Adduct	[M+H]+
Actual mz	609.281
Theoretical mz	609.28
Error	0.86
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	7.0412

Identifiers and class information

Inchi key	QEVHRUUCFGRFIF-MDEJGZGSSA-N
Smiles	O=C(OC1CC2CN3CCC=4C=5C=CC(OC)=CC5NC4C3CC2C(C(=O)OC)C1OC)C6=CC(OC)=C(OC)C(OC)=C6
Superclass	Alkaloids and derivatives
Class	Yohimbine alkaloids

Plant source

Cinnamomum verum J. Presl

Convolvulus prostratus Forssk.

External sources

HMDB ID	HMDB0014351
KNApSAcK ID	C00001763
FooDB ID
DrugBank ID	DB00206
ChEBI ID	CHEBI:28487
Pubchem Compound ID	5052
PlantCyc ID
UNPD ID	UNPD120699
Coconut ID	CNP0215502
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	0
Number of non-conjugated amine groups (#amine)	1
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	8
Number of reactive functional groups (#rtvFG)	2
Predicted central nervous system activity (CNS)	1
Molecular weight (mol_MW)	608.687
Computed dipole moment(dipole)	4.139
Total solvent accessible surface area (SASA)	880.605
Hydrophobic component of SASA (FOSA)	668.024
Hydrophilic component of SASA (FISA)	69.166
Pie component of the SASA (PISA)	143.416
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	1756.36
Number of hydrogen bond donors (donorHB)	1
Number of hydrogen bond acceptors (accptHB)	10.7
Free energy of solvation of dipole (dip^2/V)	0.0097545
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0121507
Globularity descriptor (glob)	0.799452
Predicted polarizability in cubic angstroms (QPpolrz)	60.368
Predicted hexadecane/gas partition coefficient (QPlogPC16)	16.132
Predicted octanol/gas partition coefficient (QPlogPoct)	27.214
Predicted water/gas partition coefficient (QPlogPw)	13.524
Predicted octanol/water partition coefficient (QPlogPo/w)	4.944
Predicted aqueous solubility (QPlogS)	-5.593
Conformation-independent predicted aqueous solubility (CIQPlogS)	-7.119
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-6.187
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	545.628
Predicted brain/blood partition coefficient (QPlogBB)	-0.242
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	284.345
Predicted skin permeability, log Kp (QPlogKp)	-3.584
PM3 calculated ionization potential (IP(ev))	8.038
PM3 calculated electron affinity (EA(eV))	0.523
Number of likely metabolic reactions (#metab)	7
Prediction of binding to human serum albumin (QPlogKhsa)	0.857
Predicted qualitative human oral absorption (HumanOralAbsorption)	2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	78.962
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	110.525
Number of nitrogen and oxygen atoms (#NandO)	11
Number of violations of Lipinski’s rule of five (RuleOfFive)	2
Number of violations of Jorgensen’s rule of three (RuleOfThree)	1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P21728	DRD1	Dopamine D1 receptor	T22118	SEA
P21918	DRD5	Dopamine D5 receptor	T46828	SEA
P18825	ADRA2C	Adrenergic receptor alpha-2	T01777	SEA
P08183	ABCB1	P-glycoprotein 1	T25258	SwissTargetPrediction and SEA
P35372	OPRM1	Mu opioid receptor	T47768	SwissTargetPrediction
P18089	ADRA2B	Alpha-2b adrenergic receptor	T41580	SEA
Q9UNQ0	ABCG2	ATP-binding cassette sub-family G member 2	T56556	SEA
Q9H4B7	TUBB1	Tubulin beta-1 chain	T84397	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T22118	DI0003	Abortion	[ICD-11: JA00]	P21728	DRD1
T22118	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P21728	DRD1
T22118	DI0190	Hypertension	[ICD-11: BA00-BA04]	P21728	DRD1
T22118	DI0331	Parkinsonism	[ICD-11: 8A00]	P21728	DRD1
T46828	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P21918	DRD5
T01777	DI0166	Glaucoma	[ICD-11: 9C61]	P18825	ADRA2C
T01777	DI0190	Hypertension	[ICD-11: BA00-BA04]	P18825	ADRA2C
T01777	DI0196	Hypotension	[ICD-11: BA20-BA21]	P18825	ADRA2C
T01777	DI0308	Obesity	[ICD-11: 5B80-5B81]	P18825	ADRA2C
T01777	DI0310	Ocular disease	[ICD-11: N.A.]	P18825	ADRA2C
T01777	DI0396	Substance abuse	[ICD-11: 6C40]	P18825	ADRA2C
T25258	DI0238	Lung cancer	[ICD-11: 2C25]	P08183	ABCB1
T47768	DI0013	Acute pain	[ICD-11: MG31]	P35372	OPRM1
T47768	DI0059	Bowel habit change	[ICD-11: ME05]	P35372	OPRM1
T47768	DI0087	Chronic pain	[ICD-11: MG30]	P35372	OPRM1
T47768	DI0101	Corneal disease	[ICD-11: 9A76-9A78]	P35372	OPRM1
T47768	DI0105	Cough	[ICD-11: MD12]	P35372	OPRM1
T47768	DI0117	Depression	[ICD-11: 6A70-6A7Z]	P35372	OPRM1
T47768	DI0124	Digestive system disease	[ICD-11: DE2Z]	P35372	OPRM1
T47768	DI0218	Irritable bowel syndrome	[ICD-11: DD91]	P35372	OPRM1
T47768	DI0228	Large intestine motility disorder	[ICD-11: DB32]	P35372	OPRM1
T47768	DI0317	Opioid use disorder	[ICD-11: 6C43]	P35372	OPRM1
T47768	DI0324	Pain	[ICD-11: MG30-MG3Z]	P35372	OPRM1
T47768	DI0349	Pruritus	[ICD-11: EC90]	P35372	OPRM1
T47768	DI0374	Sensation disturbance	[ICD-11: MB40]	P35372	OPRM1
T41580	DI0396	Substance abuse	[ICD-11: 6C40]	P18089	ADRA2B
T56556	DI0218	Irritable bowel syndrome	[ICD-11: DD91]	Q9UNQ0	ABCG2
T56556	DI0366	Rheumatoid arthritis	[ICD-11: FA20]	Q9UNQ0	ABCG2
T84397	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	Q9H4B7	TUBB1